Supplementary Figure 6: Knock-in and validation of novel bortezomib-resistant PSMB5 variants.
From: Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells
Bortezomib resistant mutations observed in PSMB5 (Fig. 3d) were knocked-in to K562 cells and populations were selected with bortezomib. The corresponding PSMB5 exons for the five most viable mutations were amplified, cloned into pCR-Blunt, and sequenced individually. Shown is a table summarizing the sequences of individual colonies with mutations or insertions/deletions shown in red; the targeted base is in bold.
